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t.bstract Photo-oxidized low-density lipoprotein is cytotoxic to 
bovine aortic endothelial cells in a concentration-dependent man- 
net. Total cell killing occurs at a concentration of 600 ttmoi/l lipid 
hydroperoxide (LOOH). Selenium deficiency enhances the toxic- 
ity of LOOH such that 300 ttmol/I LOOH is cytotoxic. This 
toxicity is inhibited by desferrioxamine, a transition metal ion 
chelator, and by butylatedhydroxytoluene, a potent inhibitor of 
lipid peroxidation. Toxicity is also inhibited by the nitric oxide 
donors S-nitrosoglutathione and spermine NONOate but not by 
reduced or oxidized glutathione and spermine. We propose that 
nitric oxide, released from these compounds, is inhibiting the 
toxicity of LOOH to selenium-deficient endothelial cells. Fur- 
thermore we hypothesize that the mechanism for this inhibition 
of toxicity is the scavenging of the propagatory peroxyl and 
alkoxyl free radicals, by nitric oxide, that are generated uring 
peroxidation of cell membranes. 
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1. Introduction 
The interactions between low-density lipoprotein (LDL) and 
vascular endothelial cells are likely to play a key role in the 
underlying pathology of atherosclerosis. Endothelial cells act 
as a barrier between the blood and the thrombogenic connec- 
tive and smooth muscle tissues that are present in the vessel 
wall, In atherosclerotic lesions the integrity of the endothelium 
can be compromised and such areas of damage may become the 
loci of thrombus formation and growth factor release [1]. It is 
of great interest o understand the molecular mechanisms that 
lead to endothelial cell damage and to explore ways in which 
this damage can be inhibited. The discovery that oxidized LDL, 
a form of LDL that is thought o be generated in an atheroscle- 
rotic lesion [2], is toxic to endothelial cells in culture indicates 
a possible mechanism for endothelial cell damage [3]. It is 
widely believed that such damage occurs by free radical-medi- 
ated oxidation of cellular phospholipids, leading to loss of in- 
tegrity of the cell membrane [4-6]. 
The role of nitric oxide in the atherosclerotic process has 
become a subject of interest. It has been shown that macroph- 
ages, activated to generate nitric oxide, have a reduced ability 
to oxidize LDL, and that this effect is counteracted by nitric 
oxide synthase inhibitors [7,8]. We have previously shown that 
nitric oxide donors can inhibit both chemical [9] and cell-de- 
pendent LDL oxidation [10] by a process likely to involve the 
scavenging of propagatory lipid-derived free radicals. 
*Corresponding author. Fax: (1) (414) 266-8515. 
The recent observation that chronic treatment of hyper- 
cholesterolemic rabbits with inhibitors of nitric oxide synthase 
enhance lesion formation [11,12], together with earlier observa- 
tions that L-arginine supplementation is potentially antiathero- 
genic [13,14], support the hypothesis that nitric oxide is an 
endogenous antiatherogenic molecule [15]. In this paper we 
demonstrate that nitric oxide can inhibit another potentially 
atherogenic process; namely the toxicity of oxidized LDL to 
endothelial cells. The mechanism of this inhibition may involve 
the scavenging of cellular lipid-derived radicals in a process 
similar to nitric oxide-mediated inhibition of LDL oxidation. 
2. Materials and methods 
2.1. Chemicals and reagents 
S-Nitrosoglutathione (GSNO) was synthesized following the method 
of nitrosothiol production described by Field et al. [16]. Sperrnine 
NONOate (SNN) was purchased from Cayman Chemical Co. (Ann 
Arbor, MI). Butylatedhydroxytoluene (BHT) was purchased from 
Fisher (Itasca, IL). Desferrioxamine (DFO) was obtained from Ciba- 
Geigy (Suffern, NY). Aluminium phthalocyanine t trasulfonate 
(AIPcS4) was kindly provided by Dr. A.W. Girotti (Medical College of 
Wisconsin, Milwaukee, WI). 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide (MTT), DME-Ham's F-12 mix medium (F12), 
insulin, transferrin, L-glutamine, 10 x-trypsin-EDTA, penicillin-strep- 
tomycin solution, reduced glutathione (GSH), oxidized glutathione 
(GSSG), and spermine were purchased from Sigma Chemical Co. (St. 
Louis, MO). Fetal calf serum (FCS), defined grade, was purchased 
from Hyclone Laboratories Inc. (Logan, UT). All other chemicals were 
of the highest purity available and aqueous olutions were prepared 
with deionized, glass-distilled water. 
2.2. Cultured cells 
Bovine thoracic aortic endothelial cells (BAEC) were obtained from 
American Type Culture Collection. Cells were obtained at the third 
passage, transferred to 75 cm 2 filter vent flasks (Costar, Cambridge, 
MA) and grown to confluence (5.3 × 10 6 cells/75 cm 2) in F-12 contain- 
ing 10% FCS, insulin (10/.tg/ml), transferrin (5 flg/ml), L-glutamine (4 
mmol/1), penicillin (100 U/ml) and streptomycin (100 gtg/ml), incubated 
at 37°C in a humidified atmosphere of 5% CO2 and 95% air. All 
experiments were performed in a similar medium containing 2% FCS, 
Cells were passaged as described by Balla et al. [17] and used between 
passages 6 and 13. 
Selenium-deficient cells were prepared as described by Thomas et al. 
[16]. Serum concentration was decreased from 10% to 5%, and one 
population of cells, designated Se(-), was grown without added sele- 
nium while a separate population, designated Se(+), was grown in the 
presence of sodium selenite (10 ng/ml). Serum content of both cell 
populations was maintained at5% in 75 cm 2 flasks for each consecutive 
passage. Cells were then passaged to 96-well (0.32 cm 2) tissue culture 
plates. Typically, BAEC grew to confluence (0.023 x l0  6 cells/0.32 cm 2) 
2-3 days after passaging. Confluent Se(-) and Se(+) cells did not differ 
in their total protein content, as determined by the method of Lowry 
et al. [18], using serum albumin as the standard. 
2.3. Cell viability 
MTT staining was used as an indicator of cell viability. This assay 
0014-5793195l$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(95)00178-6 
292 A.T. Struck et al./FEBS Letters 361 (1995) 291-294 
is based upon the reduction of MTT to a colored formazan crystal by 
mitochondrial dehydrogenases [19]. MTT stock solution was made up 
at 5 mg/ml in PBS and stored at 0°C. Following experimentation, the 
medium was removed and cells were incubated with a MTT (10% of 
stock) solution in F-12 with 1% penicillin/streptomycin for 4 h. The 
medium was then carefully removed so as not to disturb the monolayer 
of stained cells. The formazan crystals were solubilized in isopropanol 
and the absorbance at 570 nm recorded. A close correlation between 
the MTT method and the clonogenic method of determining cell viabil- 
ity has been reported [20]. The term 'cell viability' in this paper refers 
to the total mitochondrial activity of a treated population of cells 
normalized to that of a population of untreated cells and expressed as 
a percentage. 
2.4. Preparation of LDL and photooxidized LDL ( LDLox) 
Plasma was obtained from fasted human donors; EDTA (1 mmol/l) 
was present during all stages of isolation. LDL was isolated by ultracen- 
trifugal flotation in KBr (density range: 1.019 1.063 g/ml) [21]. All steps 
were carried out with chelex-treated and argon-purged solutions. Be- 
fore use, LDL were dialyzed against chelex-treated PBS to remove 
EDTA, and stored under argon at 4°C. Protein was determined by the 
method of Lowry et al. [18]. Preparations of LDL typically contained 
less than 5 nmol lipid hydroperoxide (LOOH)/mg protein (determined 
iodometrically) and less than 1 nmol malondialdehyde (MDA)/mg pro- 
tein (determined by reaction with thiobarbituric acid). LDL was sub- 
jected to AIPcS4-sensitized photoperoxidation [6]. A solution contain- 
ing LDL (1.0 mg protein/ml) was aliquoted into two tubes. One tube 
received no treatment and was immediately placed on ice, under argon 
(LDLn), and the other tube received 20/.tmol/1 AIPcS4. A small volume 
of this was set aside before irradiation as a 'dark control' (LDLdc). The 
remainder was irradiated at 10°C in a 5 ml vial placed within a larger 
thermostatted beaker which was covered with a clear piece of glass to 
block UV light [6]. The light source was a 90-W quartz-halogen lamp 
positioned -15 cm above the reaction vial. Incident light intensity ~ 30 
mW/cm 2, as measured with a YSI radiometer (Yellow Springs, OH). 
Solutions were continuously stirred and left open to the air during 
irradiation. Just before use and following filter-sterilization (0.22/tin) 
stock preparations of LDLox, LDLdc and LDLn were analyzed for 
LOOH content by the iodometric method [22]. 
2.5. Experimental conditions 
Se(-) or Se(+) BAEC were grown to confluence and overlaid with 
fresh medium containing 2% FCS. LDL and other compounds were 
added before incubation at 37°C in 5% COJ95% air. In each experi- 
ment the total LDL content (LDLn plus LDLox) was kept constant. 
Thus, the concentration of LDL-lipid and LDL-protein were constant 
at all LOOH concentrations. After incubation the medium was re- 
moved and the viability was determined by the MTT assay. In some 
experiments he medium was assayed for LOOH. BHT was made up 
in ethanol and added to give a final concentration f0.5% ethanol. All 
other compounds were dissolved in medium and filtered immediately 
before use. 
3. Results 
Photooxidation of LDL in the presence of AIPcS4 (20/zmol/1) 
resulted in the accumulation of LOOH but no detectable in- 
crease in TBARS. An identical sample that was kept in the dark 
did not accumulate LOOH. Aliquots of LDLox were mixed 
with aliquots of LDLn in order to generate a range of concen- 
trations of LOOH while maintaining the same concentration of
total LDL. A parallel set of samples were prepared in which 
LDLdc was added instead of LDLox. Fig. 1. shows the effect 
of incubating BAEC with increasing concentrations of LOOH. 
LOOH is not toxic to BAEC grown in selenium-replete medium 
at concentrations less than 500 pmol/l. However, if the cells are 
grown in conditions which deplete the selenium content of the 
cell (BAEC(Se-)), toxicity is apparent at 200 pmol/1 LOOH, 
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Fig. 1. The effect of selenium deficiency on the toxicity of LOOH to 
BAEC. Increasing amounts of LDLox were mixed with decreasing 
amounts of LDLn to achieve a range of LOOH concentrations while 
maintaining a constant protein concentration. These mixtures were 
added to either BAEC(Se+) (©) or BAEC(Se-) (e). Identical amounts 
of LDLdc were used in place of LDLox and added to BAEC(Se-) (l). 
Cells were incubated for 18 h after which viability was determined by 
the MTT assay, Data points represent mean _+ S.D. (n = 5). 
This agrees well with previous data using lactate dehydrogenase 
as an index of viability [6]. Loss of cell viability was not due to 
MDA formation as MDA levels remained unchanged through- 
out exposure and authentic MDA was not toxic to BAEC(Se-)  
at concentrations of -< 5 mM (data not shown). 
Addition of LDLdc to BAEC(Se-)  by an identical protocol 
produced marginal toxicity that was independent of the LDLdc 
concentration (Fig. 1) and was not affected by DFO (20 pmol/1) 
or BHT (100 ¢tmol/l) (data not shown). This toxicity was also 
apparent when LDLn containing no AIPcS 4 was used and 
incubation with an identical volume of PBS resulted in no loss 
of viability (data not shown). This probably represents an in- 
herent toxicity of LDLn which is independent of LOOH con- 
centration. The zero point toxicity was reversed by sub-lethal 
concentrations of LOOH. The mechanism whereby low levels 
of hydroperoxide are able to reverse and/or protect against 
LDLn-mediated toxicity is unclear and is presently under inves- 
tigation. This effect may be related to the known proliferative 
effect of sub-lethal concentrations of peroxide [23]. 
The effects of the nitric oxide donors GSNO and spermine 
NONOate on the toxicity of LDLox to BAEC(Se-)  are shown 
in Fig. 2. Fig. 2A shows the effect of GSNO on LOOH-depend- 
ent endothelial cell death. As in Fig. 1, toxicity was observed 
in controls at 200/zmol/1 LOOH with a complete cell kill at 300 
¢tmol/l LOOH. The breakdown products of GSNO, namely 
GSH (500 ¢tmol/1) and GSSG (500/tmol/1) had little effect on 
the toxicity of LOOH. GSNO (250/.tmol/1), however, afforded 
protection against toxicity at up to 400/lmol/1 LOOH. Pre- 
treatment of the cells with GSNO (250 pmol/l) for 5 h followed 
by removal of GSNO before the addition of LOOH afforded 
no protection. This indicates that the inhibition of toxicity by 
GSNO was not due to a stable phenotypic hange in cellular 
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i~ig. 2. The effect of GSNO and spermine NONOate on the toxicity of 
LOOH to BAEC(Se-). (A) Increasing amounts of LDLox were mixed 
with decreasing amounts of LDLn to achieve arange of LOOH concen- 
rations while maintaining a constant protein concentration. These 
:nixtures were added to BAEC(Se-) in the absence (o) or presence of 
'~]SNO (©, 500 flmol/l), GSH (i, 500,umol/1) and GSSG ([], 500/~mol/l), 
Cells were incubated for 18 h after which viability was determined by 
1:he MTT assay. (B) LDLox containing LOOH (500/1moll1) was incu- 
Oared with BAEC(Se-) cells in the absence (e) and presence of GSNO 
©, 500 flmol/l) and spermine NONOate ( t  500/~mol/l). Viability was 
,tetermined as a function of time using the MTT assay. Data points 
~epresent mean + S.D. (n = 5). 
resistance to oxidative stess. The inhibition of LDLox toxicity 
by GSNO was not due to the destruction of endogenous LOOH 
by NO or GSNO as exposure of LDLox to GSNO did not 
affect the concentration of LOOH in the presence and absence 
of BAEC(Se-) (data not shown). 
The protective ffect of GSNO may be ascribed to either the 
GSNO itself or to NO released by GSNO over the course of 
the experiment. To assess this, a second nitric oxide donor, 
spermine NONOate was used as the source of nitric oxide. Fig. 
2B shows the kinetics of LOOH (500 pmol/l)-induced cell kill- 
ing. The majority of cell death occurs within the first 5 h of 
incubation. However, it is not until 24 h that complete toxicity 
is observed. In the presence of spermine NONOate (250/.tmol/ 
1), a dramatic inhibition of LOOH toxicity was observed over 
24 h (Fig. 2B) whereas spermine (500/1moll1) alone had no 
effect on LOOH toxicity over this time range (data not shown). 
GSNO (250 pmol/l) also inhibited toxicity at all time points 
throughout he experiment. Spermine NONOate, spermine, 
GSNO, GSSG and GSH had no intrinsic toxicity to 
BAEC(Se-) at the concentrations u ed in this study. 
The effects of BHT and DFO on the toxicity of LOOH were 
examined. Experiments were performed in an identical manner 
to Fig. 1 with total LDL remaining constant. The addition of 
the transition metal ion chelator DFO (200 pmol/l) afforded 
significant protection such that complete toxicity was not ap- 
parent until concentrations of LOOH greater than 500 pmol/l 
were used (data not shown). BHT (50/lmol/l), a lipophilic free 
radical scavenger, afforded protection up to 600 pmol/1 LOOH, 
and total cell death was only achieved at 800/lmol/1 LOOH 
(data not shown). These are in agreement with previous reports 
detailing the effects of inhibiting lipid peroxidation on the tox- 
icity of hydroperoxides to endothelial cells [4-6]. 
4. Discussion 
In this study, we have deliberately sensitized endothelial cells 
to peroxide-dependent cell damage by selenium depletion. The 
effects of selenium depletion are clearly observed in Fig. 1. One 
major result of selenium depletion is the reduction of GPx and 
PHGPx activities [6]. This may be responsible for the dramatic 
enhancement in the toxicity of oxidized LDL in selenium-defi- 
cient cells. Our experiments were designed so as to minimize the 
number of components that vary with lipid hydroperoxide. 
Thus total phospholipid, protein and cholesterol are constant 
at all concentrations of LOOH. However, the unavoidable oss 
of LDL antioxidants during photo-oxidation means that these 
molecules (e.g. vitamin E, fl-carotene) also varied with LOOH 
concentration. 
GSNO and spermine NONOate are structurally unrelated 
compounds that release nitric oxide by different mechanisms. 
Spermine NONOate spontaneously decays to spermine and 
liberates two molecules of nitric oxide per molecule of spermine 
NONOate. The half life of decomposition has been measured 
as 39 min [24]. GSNO decomposition is more complex as the 
molecule is inherently stable and probably requires trace 
amounts of catalytic transition metal ions to release nitric oxide 
[25]. This process is still slow, but accelerated nitric oxide re- 
lease can occur if transnitrosylation to form a more unstable 
nitrosothiol occurs [26], e.g. the formation of S-nitrosocysteine 
from cysteine. Upon decomposition GSNO gives GSSG, but 
after transnitrosylation GSH is the product. For this reason 
both GSSG and GSH were used as controls. 
Both GSNO and spermine NONOate dramatically inhibit 
the toxicity of LDLox to BAEC(Se-). The exact mechanism of 
this inhibition is at present unknown, although we postulate 
that nitric oxide is acting as an inhibitor of lipid peroxidation 
in cells. Wink et al. [27] have shown that nitric oxide released 
from compounds with the NONOate moiety reduced the cyto- 
toxic effects of superoxide/hydrogen peroxide in lung fibrob- 
lasts and neuronal cells. The investigators have suggested that 
the cytoprotective effect of nitric oxide could be due to radical 
scavenging. We have previously suggested [9] that nitric oxide 
is able to inhibit lipid oxidation by scavenging lipid peroxyl 
radicals, thus terminating the lipid peroxidation chain reaction. 
Recently, Rubbo et al. [28] have demonstrated the formation 
of nitric oxide-lipid adducts during the oxidation of linolenic 
acid by xanthine/xanthine oxidase/iron i the presence of nitric 
oxide, and that nitric oxide inhibited this oxidation. 
It has been previously reported that the cytotoxic effects of 
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modified LDL to endothelial cells can be prevented by inclu- 
sion of antioxidants in the culture medium [4,29-31]. Inhibition 
of the toxicity of LOOH by BHT and DFO implies a role for 
the propagation of lipid peroxidation i  the toxicity process. 
Lipid oxidation occurring at the level of the LDL particle may 
generate toxic aldehydes such as malondialdehyde (MDA) and 
4-hydroxynonenal [32]. MDA, at least, is not responsible for 
the observed toxicity as little MDA is present or is generated 
during the course of the toxicity experiment and MDA is not 
toxic to BAEC(Se-) at concentrations (>5 mmol/1) far in excess 
of what could conceivably be generated by LDL oxidation. 
During the time course of oxidation, the levels of LOOH re- 
mained unaltered indicating that no direct reaction between 
nitric oxide and LOOH was occurring and that the LDL in the 
medium was not being significantly oxidized. 
Lipid peroxidation occurring at the level of the cell mem- 
brane could potentially disrupt cellular integrity by changing 
the permeability of the lipid bilayer to solutes and by damaging 
membrane transport systems. This mechanism would require 
the transfer of lipid hydroperoxides from LDL to the cell mem- 
brane. The fraction of LOOH transferring to the cell membrane 
may only be 1-2% of total LOOH and would thus not be 
detectable as a loss of LDL-LOOH. The effects of selenium 
depletion strongly suggest that transfer is occurring as GPx and 
PHGPx are intracellular enzymes and unlikely to be available 
to extracellular LDL. Transfer of peroxide to the cell could 
occur either by an active uptake mechanism or by passive 
transfer upon collision. It is also possible that the hydroperox- 
ide itself exhibits direct oxicity by interfering with a vital cellu- 
lar process and that BHT and DFO act by inhibiting propaga- 
tion in the cell membrane, thereby lowering the net accumula- 
tion of peroxides. 
The inhibition of the toxicity of oxidized LDL to endothelial 
cells by nitric oxide represents another mechanism whereby 
nitric oxide may play an anti-atherogenic role. Endothelial cell- 
derived nitric oxide may represent a continuously generated 
vascular antioxidant that suppresses the harmful oxidative re- 
actions involved in the formation and progression of vascular 
pathologies such as atherosclerosis. 
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